HPV status predicts for improved survival following chemotherapy in metastatic squamous cell carcinoma of the oropharynx

Luke R.G. Pike, William L. Hwang, Trevor J. Royce, Nina N. Sanford, Brandon A. Mahal

Research output: Contribution to journalArticle

Abstract

Objective: We sought to further define prognostic and predictive value of human papillomavirus (HPV) status in metastatic squamous cell carcinoma of the oropharynx (OPC). Materials and methods: A Surveillance, Epidemiology, and End Results custom database identified 5940 adult patients, >18-years-old, with primary SCCHN and known HPV status, diagnosed from 2013 to 2014. Wilcoxon rank-sum and Mantel-Haenszel χ2 tests compared distributions of continuous and categorical covariates. Fine-Gray competing risks regressions estimated hazard ratios by HPV status, and predictive analyses were performed including the interaction term HPV status × Receipt of Chemotherapy. Results: 182 of 5940 patients (4.0%) had metastatic OPC at diagnosis (106/3925 [2.7%] HPV+ and 76/1894 [4.0%] HPV−). HPV+ disease was prognostic for improved 20-month cancer-specific mortality (CSM) (47.1% vs 72.5%, HR 0.43, 95% CI 0.26–0.74, p = 0.002) on univariable analysis. HPV status was predictive of response to chemotherapy—adjusted HRs for receipt of chemotherapy were 0.11 (95% CI 0.03–0.37) and 0.34 (95% CI 0.18–0.64) for HPV+ versus HPV− disease, respectively (PHPV status∗Chemotherapy = 0.036). Conclusion: HPV status has known prognostic value in locally advanced OPC, but data on metastatic OPC are sparse. In this work, we demonstrate that HPV status is strongly prognostic for CSM in metastatic OPC and show for the first time that HPV status predicts for response to chemotherapy.

Original languageEnglish (US)
Pages (from-to)69-74
Number of pages6
JournalOral Oncology
Volume86
DOIs
StatePublished - Nov 2018
Externally publishedYes

Fingerprint

Oropharynx
Squamous Cell Carcinoma
Drug Therapy
Survival
Mortality
Neoplasms
Epidemiology

Keywords

  • Head and neck cancer
  • Human papillomavirus
  • Metastatic squamous cell cancer
  • Predictive biomarker
  • Systemic therapy

ASJC Scopus subject areas

  • Oral Surgery
  • Oncology
  • Cancer Research

Cite this

HPV status predicts for improved survival following chemotherapy in metastatic squamous cell carcinoma of the oropharynx. / Pike, Luke R.G.; Hwang, William L.; Royce, Trevor J.; Sanford, Nina N.; Mahal, Brandon A.

In: Oral Oncology, Vol. 86, 11.2018, p. 69-74.

Research output: Contribution to journalArticle

Pike, Luke R.G. ; Hwang, William L. ; Royce, Trevor J. ; Sanford, Nina N. ; Mahal, Brandon A. / HPV status predicts for improved survival following chemotherapy in metastatic squamous cell carcinoma of the oropharynx. In: Oral Oncology. 2018 ; Vol. 86. pp. 69-74.
@article{a917d81a9ea9403b8e2dda3aace754da,
title = "HPV status predicts for improved survival following chemotherapy in metastatic squamous cell carcinoma of the oropharynx",
abstract = "Objective: We sought to further define prognostic and predictive value of human papillomavirus (HPV) status in metastatic squamous cell carcinoma of the oropharynx (OPC). Materials and methods: A Surveillance, Epidemiology, and End Results custom database identified 5940 adult patients, >18-years-old, with primary SCCHN and known HPV status, diagnosed from 2013 to 2014. Wilcoxon rank-sum and Mantel-Haenszel χ2 tests compared distributions of continuous and categorical covariates. Fine-Gray competing risks regressions estimated hazard ratios by HPV status, and predictive analyses were performed including the interaction term HPV status × Receipt of Chemotherapy. Results: 182 of 5940 patients (4.0{\%}) had metastatic OPC at diagnosis (106/3925 [2.7{\%}] HPV+ and 76/1894 [4.0{\%}] HPV−). HPV+ disease was prognostic for improved 20-month cancer-specific mortality (CSM) (47.1{\%} vs 72.5{\%}, HR 0.43, 95{\%} CI 0.26–0.74, p = 0.002) on univariable analysis. HPV status was predictive of response to chemotherapy—adjusted HRs for receipt of chemotherapy were 0.11 (95{\%} CI 0.03–0.37) and 0.34 (95{\%} CI 0.18–0.64) for HPV+ versus HPV− disease, respectively (PHPV status∗Chemotherapy = 0.036). Conclusion: HPV status has known prognostic value in locally advanced OPC, but data on metastatic OPC are sparse. In this work, we demonstrate that HPV status is strongly prognostic for CSM in metastatic OPC and show for the first time that HPV status predicts for response to chemotherapy.",
keywords = "Head and neck cancer, Human papillomavirus, Metastatic squamous cell cancer, Predictive biomarker, Systemic therapy",
author = "Pike, {Luke R.G.} and Hwang, {William L.} and Royce, {Trevor J.} and Sanford, {Nina N.} and Mahal, {Brandon A.}",
year = "2018",
month = "11",
doi = "10.1016/j.oraloncology.2018.09.007",
language = "English (US)",
volume = "86",
pages = "69--74",
journal = "Oral Oncology",
issn = "1368-8375",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - HPV status predicts for improved survival following chemotherapy in metastatic squamous cell carcinoma of the oropharynx

AU - Pike, Luke R.G.

AU - Hwang, William L.

AU - Royce, Trevor J.

AU - Sanford, Nina N.

AU - Mahal, Brandon A.

PY - 2018/11

Y1 - 2018/11

N2 - Objective: We sought to further define prognostic and predictive value of human papillomavirus (HPV) status in metastatic squamous cell carcinoma of the oropharynx (OPC). Materials and methods: A Surveillance, Epidemiology, and End Results custom database identified 5940 adult patients, >18-years-old, with primary SCCHN and known HPV status, diagnosed from 2013 to 2014. Wilcoxon rank-sum and Mantel-Haenszel χ2 tests compared distributions of continuous and categorical covariates. Fine-Gray competing risks regressions estimated hazard ratios by HPV status, and predictive analyses were performed including the interaction term HPV status × Receipt of Chemotherapy. Results: 182 of 5940 patients (4.0%) had metastatic OPC at diagnosis (106/3925 [2.7%] HPV+ and 76/1894 [4.0%] HPV−). HPV+ disease was prognostic for improved 20-month cancer-specific mortality (CSM) (47.1% vs 72.5%, HR 0.43, 95% CI 0.26–0.74, p = 0.002) on univariable analysis. HPV status was predictive of response to chemotherapy—adjusted HRs for receipt of chemotherapy were 0.11 (95% CI 0.03–0.37) and 0.34 (95% CI 0.18–0.64) for HPV+ versus HPV− disease, respectively (PHPV status∗Chemotherapy = 0.036). Conclusion: HPV status has known prognostic value in locally advanced OPC, but data on metastatic OPC are sparse. In this work, we demonstrate that HPV status is strongly prognostic for CSM in metastatic OPC and show for the first time that HPV status predicts for response to chemotherapy.

AB - Objective: We sought to further define prognostic and predictive value of human papillomavirus (HPV) status in metastatic squamous cell carcinoma of the oropharynx (OPC). Materials and methods: A Surveillance, Epidemiology, and End Results custom database identified 5940 adult patients, >18-years-old, with primary SCCHN and known HPV status, diagnosed from 2013 to 2014. Wilcoxon rank-sum and Mantel-Haenszel χ2 tests compared distributions of continuous and categorical covariates. Fine-Gray competing risks regressions estimated hazard ratios by HPV status, and predictive analyses were performed including the interaction term HPV status × Receipt of Chemotherapy. Results: 182 of 5940 patients (4.0%) had metastatic OPC at diagnosis (106/3925 [2.7%] HPV+ and 76/1894 [4.0%] HPV−). HPV+ disease was prognostic for improved 20-month cancer-specific mortality (CSM) (47.1% vs 72.5%, HR 0.43, 95% CI 0.26–0.74, p = 0.002) on univariable analysis. HPV status was predictive of response to chemotherapy—adjusted HRs for receipt of chemotherapy were 0.11 (95% CI 0.03–0.37) and 0.34 (95% CI 0.18–0.64) for HPV+ versus HPV− disease, respectively (PHPV status∗Chemotherapy = 0.036). Conclusion: HPV status has known prognostic value in locally advanced OPC, but data on metastatic OPC are sparse. In this work, we demonstrate that HPV status is strongly prognostic for CSM in metastatic OPC and show for the first time that HPV status predicts for response to chemotherapy.

KW - Head and neck cancer

KW - Human papillomavirus

KW - Metastatic squamous cell cancer

KW - Predictive biomarker

KW - Systemic therapy

UR - http://www.scopus.com/inward/record.url?scp=85053419280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053419280&partnerID=8YFLogxK

U2 - 10.1016/j.oraloncology.2018.09.007

DO - 10.1016/j.oraloncology.2018.09.007

M3 - Article

C2 - 30409322

AN - SCOPUS:85053419280

VL - 86

SP - 69

EP - 74

JO - Oral Oncology

JF - Oral Oncology

SN - 1368-8375

ER -